Skip to main content

Tricyclic Antidepressants

Tricyclic antidepressants (TCAs) are the most multifunctional drug class in functional urology. Their pharmacology stacks five effects relevant to the lower urinary tract — antimuscarinic, serotonin / norepinephrine reuptake inhibition, direct smooth-muscle relaxation, sodium-channel blockade, and central sleep / arousal modulation — which gives them a foothold across eight off-label and one FDA-approved urologic indication: IC/BPS, nocturnal enuresis (FDA-approved for imipramine in children), OAB / detrusor overactivity, stress and mixed urinary incontinence, CP/CPPS, chronic pelvic pain in women, nocturia (low-dose doxepin), and the "vague voiding dysfunction with frequency and pain" phenotype. Amitriptyline is the most-studied TCA in urology and is listed in the AUA IC/BPS guideline (Grade B). Imipramine holds the only FDA-approved urologic indication (childhood enuresis).[1][2]

For class-comparison context see SNRIs and Gabapentinoids. For the conditions these agents target, see IC/PBS, Chronic Pelvic Pain, and Nocturia.

Mechanism — Why TCAs Are Multifunctional in the LUT​

MechanismLUT effect
Antimuscarinic (competitive M-receptor antagonism)Reduces involuntary detrusor contractions and increases capacity. Imipramine, amitriptyline, nortriptyline, clomipramine all competitively antagonize ACh-induced bladder smooth-muscle contractions at clinical concentrations[3][4][5]
5-HT and NE reuptake inhibitionModulates the micturition reflex at spinal and supraspinal levels. Acute imipramine raises the spinal reflex threshold (serotonergic), while chronic dosing raises the supraspinal threshold via a separate mechanism[6]
Direct smooth-muscle relaxationImipramine inhibits both bethanechol- and barium chloride–induced contractions — independent of antimuscarinic effect[5]
Norepinephrine reuptake at bladder neck / urethraIncreases urethral closure pressure → potentially useful for SUI, harmful in voiding dysfunction[7][8][9]
Sodium channel blockadeLocal-anesthetic effect on bladder afferent nerves — relevant to IC/BPS pain
Central sleep / arousal modulationImproves arousability — contributes to enuresis efficacy beyond antimuscarinic mechanism; explains why imipramine works in some children who fail anticholinergic monotherapy[10][11]

Agent comparison​

AgentPrimary urologic roleAnticholinergic potencyFDA urologic indication
ImipramineEnuresis, OAB, SUI, mixed UIModerateYes — childhood enuresis[2]
AmitriptylineIC/BPS, CPP, nocturiaHighest among TCAsNo
NortriptylineOAB / frequency, CPPLower than amitriptylineNo[16]
DoxepinDO, sleep-fragmentation nocturiaModerate; potent antihistamineYes for insomnia at 3–6 mg (not urologic)[18]
DesipramineNeuropathic CPP componentLowest of the TCAsNo
Clomipramine(Adverse-effect concern: urinary retention)HighNo

IC/BPS — the most evidence-based urologic application​

The 2022 AUA IC/BPS Guideline lists amitriptyline as an oral medication option (Statement 14) — alphabetically alongside cimetidine, hydroxyzine, and pentosan polysulfate, with no hierarchy. Evidence Strength Grade B.[1][20]

Mechanism in IC/BPS​

Amitriptyline's stacked effects fit IC/BPS particularly well — antimuscarinic for urgency/frequency, central + peripheral analgesia for pain, antihistamine effect on mast-cell-mediated pathophysiology, and sedation that improves nocturia-disrupted sleep.[20]

Pivotal RCT — van Ophoven 2004​

50 patients, prospective placebo-controlled double-blind, amitriptyline self-titrated 25 mg weekly to max 100 mg/day × 4 months:[14]

  • Mean ICSI 26.9 → 18.5 (amitriptyline) vs 27.6 → 24.1 (placebo) — p = 0.005
  • Pain and urgency intensity improved significantly (p < 0.05)
  • Anticholinergic AEs in 92%

Treatment-naïve RCT — Foster 2010​

Multicenter (n = 271 treatment-naïve), amitriptyline 10 → 75 mg/day × 6 weeks + standardized education / behavioral modification, 12-week follow-up:[21]

  • Primary endpoint (moderate/marked GRA): 55% vs 45% (p = 0.12) — not significant
  • Subgroup achieving ≥ 50 mg/day (n = 207): 66% vs 47% (p = 0.01) — defines a dose threshold for efficacy

Network meta-analysis 2021​

ICSI significantly reduced vs placebo (MD −4.9, 95% CI −9.0 to −0.76); amitriptyline ranked among the agents capable of significantly lowering ICSI alongside cyclosporine A and certolizumab pegol.[22]

AUA dosing​

Start 10 mg QHS; titrate to 75–100 mg if tolerated. Anticholinergic AEs are common (sedation, drowsiness, nausea) and frequently QoL-limiting.[1]

Nocturnal Enuresis — the only FDA-approved urologic indication​

Imipramine is FDA-approved as adjunctive therapy for nocturnal enuresis in children ≥ 6 years after organic causes are excluded.[2]

Dosing[2]​

  • Start 25 mg 1 h before bedtime
  • May increase to 50 mg/day (ages 6–12) or 75 mg/day (> 12)
  • Max 75 mg/day or 2.5 mg/kg/day
  • Consider drug-free intervals after adequate response; taper gradually

Cochrane evidence (58 RCTs, 3,721 children)[10][11]​

  • ~ 1 fewer wet night per week vs placebo (MD −0.95)
  • About 1 in 5 children become dry on imipramine
  • 78% fail to achieve 14 consecutive dry nights on imipramine vs 95% on placebo (RR 0.74)
  • Imipramine + oxybutynin more effective than placebo (33% vs 78% failure to achieve 14 dry nights; RR 0.43)
  • High relapse on discontinuation

Safety[11][23]​

  • Cardiotoxicity — arrhythmias, QT prolongation; obtain baseline ECG
  • Overdose lethality — TCAs are among the most dangerous drugs in overdose; ICCS recommends imipramine only after all other therapies have failed
  • Mood changes and sleep disturbance common
  • Store securely away from younger siblings

Current role​

Third-line — after alarm therapy and desmopressin; combined with oxybutynin in refractory cases.[11][23]

OAB / Detrusor Overactivity​

TCAs reduce detrusor overactivity through three convergent mechanisms — antimuscarinic blockade, direct smooth-muscle relaxation, and central modulation of the micturition reflex.[7][24]

Selected evidence​

  • Castleden 1981 — imipramine titrated to 150 mg QHS in 10 elderly patients with unstable detrusor: continence in 6/10 (60%), with mean +105 mL capacity, −18 cm H₂O bladder pressure at capacity, +30 cm H₂O urethral pressure[9]
  • Lose 1989 (doxepin) — double-blind crossover RCT in 19 women with detrusor overactivity refractory to conventional therapy; doxepin 50 mg QHS ± 25 mg AM significantly decreased nighttime micturitions and nighttime incontinence episodes[17]
  • Servadio 1975 (nortriptyline) — open study in 40 women with chronic frequency, urgency, dysuria; nortriptyline produced considerable improvement or total resolution in 75%; in vitro confirmed antimuscarinic activity[15]

Current role​

Largely supplanted by modern antimuscarinics and β3-agonists; retained as adjuncts when comorbid pain, depression, or insomnia makes a TCA advantageous.[24][25][26][27]

Stress and Mixed Urinary Incontinence​

Imipramine's NE-reuptake inhibition at the bladder neck and proximal urethra raises urethral closure pressure — the rationale for its off-label SUI use.[7][8][28][29]

Evidence​

  • Gilja 1984 — 30 women with SUI on imipramine 75 mg/day × 4 weeks: continence in 21/30 (71%); functional urethral length extended and stress-resistant in responders[8]
  • No RCTs exist in SUI; use rests on uncontrolled studies and pharmacologic rationale[28]

Mixed incontinence​

The dual antimuscarinic + noradrenergic profile theoretically covers urge and stress components — but no head-to-head data support this in mixed UI.[28]

Comparison with duloxetine​

Duloxetine (SNRI) is the only agent in this pharmacologic class with Phase III RCT data for SUI — approved in Europe, not FDA-approved in the US (suicide-risk concern). Imipramine's broader receptor coverage is theoretical; the absence of RCT data limits formal recommendations.[28][29]

CP/CPPS​

TCAs are part of the "N" (Neurologic / Systemic) domain of the UPOINT system for CP/CPPS — used for the neuropathic-pain component when present.[31]

  • Cochrane 2019: antidepressants (including TCAs) may be ineffective for prostatitis-symptom reduction (low- to very-low-quality evidence); GI discomfort, decreased libido, ejaculatory disorders, sedation, and dizziness were common AEs[30]
  • Multimodal UPOINT-directed therapy improves symptoms in 75–84% of patients across three independent studies — TCAs are a recognized component[31]
  • Real-world prescribing pattern: in the Agarwal UCPPS comparison, 13.6% of gabapentin patients required adjunctive amitriptyline vs 44% of pregabalin patients (p = 0.0001) — an indirect signal that amitriptyline is commonly added when gabapentinoids fall short[32]
  • TCAs are not first-line monotherapy; use as part of multimodal phenotype-directed therapy when neuropathic features, sleep disturbance, or comorbid depression are present[33]

Chronic Pelvic Pain in Women​

ACOG (2020) recognizes TCAs as commonly used for neuropathic pain but cites only weak evidence for CPP specifically. SNRIs are favored at Level B for neuropathic CPP. A 2009 RCT showed gabapentin + nortriptyline outperformed either alone for neuropathic pain.[12]

The 2021 JAMA CPP review concludes TCAs "help with associated mood, sleep, and neuropathic pain symptoms and may in turn improve quality of life but only provide minimal improvements in pain."[13]

Practical: second-line to SNRIs; preferred when comorbid insomnia or depression coexists, or when combined with gabapentinoids for synergistic neuropathic relief.[12][13]

Nocturia​

Low-dose doxepin (3–6 mg)​

FDA-approved for sleep-maintenance insomnia at 3–6 mg.[18][34][35] At these sub-antidepressant doses doxepin acts primarily as a potent H1 antihistamine with minimal antimuscarinic burden — a useful niche for nocturia driven by sleep fragmentation and frequent cortical arousals (rather than by polyuria or reduced bladder capacity).[35][37]

Amitriptyline at higher doses​

Adds antimuscarinic detrusor effects on top of sedation — useful in IC/BPS-pattern nocturia (van Ophoven RCT showed a trend toward reduced frequency).[14] A chart review in 22 patients with frequency and pain on amitriptyline 25–100 mg: 11 symptom-free and 6 significantly improved (~77%); 15 who tapered after 6 months relapsed early — favoring maintenance therapy.[36]

"Vague Voiding Dysfunction with Frequency and Pain"​

A practical niche: Pranikoff & Constantino 1998 — 22 patients (12 male, 10 female) with nonspecific urinary and pelvic / genital complaints not meeting IC criteria; amitriptyline 25–100 mg → 11 symptom-free, 6 improved, 5 non-responders (4 of whom couldn't tolerate). The authors concluded amitriptyline is "therapeutically useful in vague voiding dysfunctions, especially in the presence of urinary frequency or genital, pelvic, or suprapubic pain" in both sexes.[36]

Urologic Adverse Effects — under-recognized​

TCAs produce significant urologic AEs that matter both as treatment limitations and as diagnostic considerations when patients on TCAs present with new urinary symptoms.

Urinary retention is the most common urologic ADR​

  • A pharmacovigilance study (462,661 psychiatric inpatients, 1993–2016): urinary retention was the most common urologic ADR of psychotropics; TCAs had higher risk than SSRIs; amitriptyline and clomipramine were the most common TCA culprits[19]
  • Systematic review and meta-analysis: TCAs cause voiding disorders more frequently than placebo, OR 3.30 (95% CI 1.90–5.72)[38]

FDA-label urologic / sexual / endocrine effects (TCA class)[16][2][39]​

  • Urinary retention; delayed micturition; urinary tract dilation; paradoxical frequency at low doses
  • Decreased or increased libido; erectile dysfunction; testicular swelling; ejaculatory disorders; gynecomastia in males
  • SIADH / hyponatremia — reported with all TCAs; clinically significant in elderly patients on diuretics; the amitriptyline label specifically warns about SIADH-related hyponatremia
  • Cardiovascular — QT prolongation, arrhythmias, heart block; obtain baseline ECG. Secondary amines (nortriptyline, desipramine) carry less anticholinergic burden and are generally preferred when that burden is the concern[16]

Practical Prescribing for Urologists​

IndicationAgentStartTargetTiming
IC/BPSAmitriptyline10 mg QHS75–100 mg QHS (efficacy threshold ≥ 50 mg)[1][21]Bedtime
Nocturnal enuresis (≥ 6 yr)Imipramine25 mg QHS50–75 mg QHS[2]1 h pre-bed
OAB / detrusor overactivityImipramine25 mg QHS75–150 mg QHS[9]Bedtime
Detrusor overactivity (refractory)Doxepin50 mg QHS50–75 mg/day[17]Bedtime ± AM
SUI / mixed UIImipramine25 mg/day75 mg/day[8]Divided or QHS
CP/CPPSAmitriptyline or nortriptyline10–25 mg QHS50–75 mg QHS[31][32][33]Bedtime
CPP (women)Nortriptyline or amitriptyline10 mg QHS50–75 mg QHS[12]Bedtime
Nocturia (sleep-fragmentation phenotype)Doxepin3 mg QHS6 mg QHS[18]30 min pre-bed

Cross-cutting precautions​

  • MAO inhibitors — contraindicated; serotonin syndrome / hypertensive crisis; ≥ 14-day washout[39]
  • Anticholinergic burden — TCAs add to cumulative anticholinergic load with antimuscarinics; monitor for retention, constipation, cognitive impairment, particularly in older adults[19][38]
  • QT-prolonging drugs — avoid combinations with fluoroquinolones, antiarrhythmics; baseline ECG
  • Older adults — TCAs are on the AGS Beers Criteria as potentially inappropriate; secondary amines preferred if a TCA is necessary[16]
  • Overdose risk — TCAs are lethal in overdose (cardiac arrhythmia, seizure); prescribe limited quantities in patients with suicidality[11]
  • Guanethidine interaction — amitriptyline can blunt the antihypertensive effect[39]

TCAs vs SNRIs vs Gabapentinoids — Quick Positioning​

FeatureTCAs (amitriptyline / imipramine)SNRIs (duloxetine)Gabapentinoids
IC/BPSAUA option (Grade B)Not studiedNo IC-specific RCTs
SUIOff-label; no RCTsPhase III RCTs; EU-approvedNot applicable
OABImipramine useful adjunctNot provenPregabalin may increase voided volume
CP/CPPSUPOINT "N" componentMixed resultsPregabalin RCT failed primary endpoint
CPP (women)Weak evidence; second-lineACOG Level BGaPP2 negative
EnuresisFDA-approved (imipramine)Not studiedNot studied
Antimuscarinic effectSignificant (helps OAB; harms retention)MinimalNone
Sexual dysfunctionCommonCommonCommon (~41%)
SedationSignificant (helps nocturia/insomnia)MinimalModerate
Cardiac riskQT prolongation; arrhythmiasMinimalMinimal
Overdose lethalityHighLowLow

Clinical Positioning​

  • Amitriptyline is the most important TCA in urology — only TCA in the AUA IC/BPS guideline (Grade B); the dose threshold for efficacy is ≥ 50 mg/day; anticholinergic AEs in ~ 92%; start 10 mg QHS and titrate[1][14][21]
  • Imipramine is the only TCA with an FDA-approved urologic indication (childhood enuresis); cuts wet nights ~ 1/wk; use as third-line after alarm and desmopressin; ECG before starting[2][10][11]
  • OAB / detrusor overactivity — TCAs largely displaced by modern antimuscarinics and β3-agonists; useful adjuncts when comorbid pain, depression, or insomnia is present[9][17][26]
  • SUI — uncontrolled imipramine data show a 71% continence rate; no RCTs; duloxetine is the only class member with Phase III SUI evidence[8][28][29]
  • CPP in either sex — TCAs help mood / sleep / neuropathic-pain comorbidities more than they help pain itself; ACOG prefers SNRIs (Level B) for neuropathic CPP[12][13]
  • Low-dose doxepin (3–6 mg) is the right tool for nocturia driven by sleep fragmentation, not polyuria[18][35]
  • Urinary retention is the most common urologic ADR of TCAs (OR 3.30 vs placebo) — actively ask about TCA use in patients with new voiding dysfunction; psychiatric prescribers should know the urologic risks in patients with pre-existing LUTS[19][38]
  • The antimuscarinic effect is a double-edged sword — therapeutic in OAB / enuresis, problematic in voiding dysfunction, BPH, or underactive bladder
  • Secondary amines (nortriptyline, desipramine) have less anticholinergic burden and are generally preferred when that burden is the concern — though amitriptyline carries the most IC/BPS-specific evidence[16]

See Also​

References​

1. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

2. US Food and Drug Administration. Imipramine Hydrochloride — prescribing information. Updated 2023-12-15.

3. Uno J, Obara K, Suzuki H, et al. "Inhibitory effects of antidepressants on acetylcholine-induced contractions in isolated guinea pig urinary bladder smooth muscle." Pharmacology. 2017;99(1-2):89–98. doi:10.1159/000452221

4. Rehavi M, Weiss H, Nissenkorn I, Rubinstein R, Cohen S. "A comparative study of the affinities of some tricyclic antidepressants for the muscarinic cholinergic receptor in human and guinea-pig bladder, ileum and brain in relation to differential drug potency." Life Sci. 1987;40(18):1819–1827. doi:10.1016/0024-3205(87)90093-2

5. Benson GS, Sarshik SA, Raezer DM, Wein AJ. "Bladder muscle contractility: comparative effects and mechanisms of action of atropine, propantheline, flavoxate, and imipramine." Urology. 1977;9(1):31–35. doi:10.1016/0090-4295(77)90279-5

6. Maggi CA, Borsini F, Lecci A, et al. "Effect of acute or chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats." J Pharmacol Exp Ther. 1989;248(1):278–285.

7. Sullivan J, Abrams P. "Pharmacological management of incontinence." Eur Urol. 1999;36(Suppl 1):89–95. doi:10.1159/000052327

8. Gilja I, Radej M, Kovacić M, Parazajder J. "Conservative treatment of female stress incontinence with imipramine." J Urol. 1984;132(5):909–911. doi:10.1016/s0022-5347(17)49941-1

9. Castleden CM, George CF, Renwick AG, Asher MJ. "Imipramine — a possible alternative to current therapy for urinary incontinence in the elderly." J Urol. 1981;125(3):318–320. doi:10.1016/s0022-5347(17)55023-5

10. Glazener CM, Evans JH. "Tricyclic and related drugs for nocturnal enuresis in children." Cochrane Database Syst Rev. 2000;(2):CD002117. doi:10.1002/14651858.CD002117

11. Robson WL. "Evaluation and management of enuresis." N Engl J Med. 2009;360(14):1429–1436. doi:10.1056/NEJMcp0808009

12. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

13. Lamvu G, Carrillo J, Ouyang C, Rapkin A. "Chronic pelvic pain in women: a review." JAMA. 2021;325(23):2381–2391. doi:10.1001/jama.2021.2631

14. van Ophoven A, Pokupic S, Heinecke A, Hertle L. "A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis." J Urol. 2004;172(2):533–536. doi:10.1097/01.ju.0000132388.54703.4d

15. Servadio C, Nissenkorn I, Zeigler M. "Nortriptyline hydrochloride in urology." Urology. 1975;5(6):747–750. doi:10.1016/0090-4295(75)90345-3

16. US Food and Drug Administration. Nortriptyline Hydrochloride — prescribing information. Updated 2026-01-07.

17. Lose G, Jørgensen L, Thunedborg P. "Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study." J Urol. 1989;142(4):1024–1026. doi:10.1016/s0022-5347(17)38976-0

18. US Food and Drug Administration. Doxepin Hydrochloride — prescribing information. Updated 2022-01-20.

19. Winkler D, Grohmann R, Friedrich ME, et al. "Urological adverse drug reactions of psychotropic medication in psychiatric inpatients — a drug surveillance report from German-speaking countries." J Psychiatr Res. 2021;144:412–420. doi:10.1016/j.jpsychires.2021.10.026

20. Chermansky CJ, Guirguis MO. "Pharmacologic management of interstitial cystitis / bladder pain syndrome." Urol Clin North Am. 2022;49(2):273–282. doi:10.1016/j.ucl.2022.01.003

21. Foster HE, Hanno PM, Nickel JC, et al. "Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis / painful bladder syndrome." J Urol. 2010;183(5):1853–1858. doi:10.1016/j.juro.2009.12.106

22. Di XP, Luo DY, Jin X, et al. "Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis." Int Urogynecol J. 2021;32(5):1129–1141. doi:10.1007/s00192-020-04659-w

23. Lauters RA, Garcia KW, Arnold JJ. "Enuresis in children: common questions and answers." Am Fam Physician. 2022;106(5):549–556.

24. Andersson KE. "Treatment of overactive bladder: other drug mechanisms." Urology. 2000;55(5A Suppl):51–57. doi:10.1016/s0090-4295(99)00495-1

25. Wein AJ. "Pharmacologic options for the overactive bladder." Urology. 1998;51(2A Suppl):43–47. doi:10.1016/s0090-4295(98)90009-7

26. Athanasopoulos A. "The pharmacotherapy of overactive bladder." Expert Opin Pharmacother. 2011;12(7):1003–1005. doi:10.1517/14656566.2011.554397

27. Loloi J, Clearwater W, Schulz A, Suadicani SO, Abraham N. "Medical treatment of overactive bladder." Urol Clin North Am. 2022;49(2):249–261. doi:10.1016/j.ucl.2021.12.005

28. Norton P, Brubaker L. "Urinary incontinence in women." Lancet. 2006;367(9504):57–67. doi:10.1016/S0140-6736(06)67925-7

29. Wu JM. "Stress incontinence in women." N Engl J Med. 2021;384(25):2428–2436. doi:10.1056/NEJMcp1914037

30. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis / chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

31. Polackwich AS, Shoskes DA. "Chronic prostatitis / chronic pelvic pain syndrome: a review of evaluation and therapy." Prostate Cancer Prostatic Dis. 2016;19(2):132–138. doi:10.1038/pcan.2016.8

32. Agarwal MM, Elsi Sy M. "Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin?" Neurourol Urodyn. 2017;36(8):2028–2033. doi:10.1002/nau.23225

33. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. "Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome." Drugs Aging. 2021;38(10):845–886. doi:10.1007/s40266-021-00890-2

34. Morin CM, Buysse DJ. "Management of insomnia." N Engl J Med. 2024;391(3):247–258. doi:10.1056/NEJMcp2305655

35. Morin CM, Benca R. "Chronic insomnia." Lancet. 2012;379(9821):1129–1141. doi:10.1016/S0140-6736(11)60750-2

36. Pranikoff K, Constantino G. "The use of amitriptyline in patients with urinary frequency and pain." Urology. 1998;51(5A Suppl):179–181. doi:10.1016/s0090-4295(98)00071-5

37. Kim J, Chung E. "Pharmacotherapeutic options in the treatment of nocturia: an update on the current oral drug therapies." Expert Opin Pharmacother. 2022;23(3):405–411. doi:10.1080/14656566.2021.2016698

38. Trinchieri M, Perletti G, Magri V, et al. "Urinary side effects of psychotropic drugs: a systematic review and metanalysis." Neurourol Urodyn. 2021;40(6):1333–1348. doi:10.1002/nau.24695

39. US Food and Drug Administration. Amitriptyline Hydrochloride — prescribing information. Updated 2026-04-08.